肿瘤标志物联合检测在宫颈癌诊断中的应用价值  

Clinical Value of the Combination Detection Serum Tumor Markers in Cervical Cancer

作　　者：童红莉[1] 李娟[1,2] 温新宇[1] 田亚平[1] 向荣[2] 

机构地区：[1]解放军总医院生化科,北京100853 [2]南开大学医学院,天津300071

出　　处：《标记免疫分析与临床》2011年第3期160-162,共3页Labeled Immunoassays and Clinical Medicine

基　　金：国家科技支撑计划课题(2009BAI86B05)

摘　　要：为探讨血清肿瘤标志物SCC、CA125、CA15-3和CA19-9联合检测在宫颈癌诊断中的意义,检测了31例宫颈癌患者、22例宫颈良性病变患者术前及53名正常对照者上述血清肿瘤标志物的水平。结果显示,宫颈癌组血清SCC、CA125和CA15-3水平显著高于宫颈良性病变组(P<0.05)和正常对照组(P<0.05)。四种血清肿瘤标志物中,单项检测宫颈癌的灵敏度以SCC最高(41.9%)。血清CA125与SCC联检可将宫颈癌检测的灵敏度提高到58.1%,特异性为72.0%,对宫颈癌的辅助诊断具有重要的意义。To investigate the clinical value of combination detection serum tumor markers SCC,CA125,CA15-3 and CA19-9 in the diagnosis of cervical cancer,the serum SCC,CA125,CA15-3 and CA19-9 levels in 31 pretreatment cervical cancer patients,22 patients with cervical benign diseases and 53 healthy subjects were detected.The results showed that the serum SCC,CA125 and CA15-3 levels in cervical cancer patients were significantly higher than in patients with cervical benign diseases and healthy control（P0.05）.The serum SCC among four serum tumor markers used alone in the diagnosis of cervical cancer showed a highest sensitivity（41.90%）.Combination detection of SCC and CA125,the sensitivity was increased to 58.1%,the specificity was 72.0%.Combination detection of serum SCC and CA125 would improve the sensitivity in cervical cancer detection.It would be helpful for the assistant diagnosis of cervical cancer.

关 键 词：宫颈癌 肿瘤标志物 联合检测 辅助诊断 

分 类 号：R737.33[医药卫生—肿瘤]